AR103972A1 - Agente terapéutico para disfunción del lóbulo frontal - Google Patents
Agente terapéutico para disfunción del lóbulo frontalInfo
- Publication number
- AR103972A1 AR103972A1 ARP160100730A ARP160100730A AR103972A1 AR 103972 A1 AR103972 A1 AR 103972A1 AR P160100730 A ARP160100730 A AR P160100730A AR P160100730 A ARP160100730 A AR P160100730A AR 103972 A1 AR103972 A1 AR 103972A1
- Authority
- AR
- Argentina
- Prior art keywords
- cognitive impairment
- disease
- dementia
- dysfunction
- lobbus
- Prior art date
Links
- 230000004064 dysfunction Effects 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 4
- 201000002832 Lewy body dementia Diseases 0.000 abstract 4
- 208000010877 cognitive disease Diseases 0.000 abstract 4
- 206010067889 Dementia with Lewy bodies Diseases 0.000 abstract 3
- 208000009829 Lewy Body Disease Diseases 0.000 abstract 3
- 208000018737 Parkinson disease Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 206010033799 Paralysis Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000037326 chronic stress Effects 0.000 abstract 1
- 210000001652 frontal lobe Anatomy 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 230000000750 progressive effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Agente terapéutico y/o preventivo, por ejemplo, para disfunción del lóbulo frontal (por ejemplo, alteración cognitiva (por ejemplo, alteración cognitiva en enfermedad de Parkinson, alteración cognitiva causada por estrés crónico, demencia con cuerpos de Lewy, parálisis supranuclear progresiva, demencia frontotemporal, y similares), y otros), enfermedad de cuerpos de Lewy (por ejemplo, alteración cognitiva en enfermedad de Parkinson, enfermedad difusa de cuerpos de Lewy, demencia con cuerpos de Lewy, trastorno del movimiento asociado con enfermedad de cuerpos de Lewy, y similares), y otros, que contiene un compuesto representado por la fórmula (1) o una de sus sales farmacéuticamente aceptables como un ingrediente activo. Compuesto, método y uso.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015055532 | 2015-03-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR103972A1 true AR103972A1 (es) | 2017-06-14 |
Family
ID=56919157
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160100730A AR103972A1 (es) | 2015-03-19 | 2016-03-18 | Agente terapéutico para disfunción del lóbulo frontal |
Country Status (39)
Country | Link |
---|---|
US (2) | US20180042910A1 (es) |
EP (1) | EP3270923B1 (es) |
JP (1) | JP6869893B2 (es) |
KR (1) | KR20170129764A (es) |
CN (1) | CN107405341A (es) |
AR (1) | AR103972A1 (es) |
AU (1) | AU2016234211B2 (es) |
BR (1) | BR112017018165A2 (es) |
CA (1) | CA2978426A1 (es) |
CL (1) | CL2017002351A1 (es) |
CO (1) | CO2017008814A2 (es) |
CR (1) | CR20170405A (es) |
CY (1) | CY1124459T1 (es) |
DK (1) | DK3270923T3 (es) |
DO (1) | DOP2017000206A (es) |
EA (1) | EA032511B1 (es) |
EC (1) | ECSP17069712A (es) |
ES (1) | ES2884846T3 (es) |
GE (1) | GEP20197007B (es) |
HK (1) | HK1249059A1 (es) |
HR (1) | HRP20211340T1 (es) |
HU (1) | HUE055387T2 (es) |
IL (1) | IL254196A0 (es) |
JO (1) | JO3544B1 (es) |
LT (1) | LT3270923T (es) |
MX (1) | MX2017012020A (es) |
MY (1) | MY196076A (es) |
PE (1) | PE20171621A1 (es) |
PL (1) | PL3270923T3 (es) |
PT (1) | PT3270923T (es) |
RS (1) | RS62311B1 (es) |
SG (1) | SG11201707012YA (es) |
SI (1) | SI3270923T1 (es) |
SV (1) | SV2017005527A (es) |
TN (1) | TN2017000369A1 (es) |
TW (1) | TWI723012B (es) |
UA (1) | UA123578C2 (es) |
WO (1) | WO2016148308A1 (es) |
ZA (1) | ZA201706136B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113016719B (zh) * | 2019-12-24 | 2022-08-02 | 复旦大学附属华山医院 | 一种突触核蛋白病理性快动眼睡眠行为障碍模型的制备法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1666041A3 (en) | 1997-09-05 | 2008-04-02 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives for treating neurodegenerative disorders |
PL1700856T3 (pl) * | 2003-12-26 | 2016-05-31 | Kyowa Hakko Kirin Co Ltd | Pochodna tiazolu |
EP2210891A1 (en) * | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
TWI548411B (zh) | 2009-04-28 | 2016-09-11 | Kyowa Hakko Kirin Co Ltd | Exercise disorder treatment |
UA113383C2 (xx) * | 2009-09-02 | 2017-01-25 | Терапевтичний агент для лікування тривожних розладів | |
UA110097C2 (uk) * | 2009-09-02 | 2015-11-25 | Терапевтичний агент для лікування розладів настрою | |
WO2012060844A1 (en) | 2010-11-05 | 2012-05-10 | Biotie Therapies, Inc | A2a antagonists as cognition and motor function enhancers |
-
2016
- 2016-03-17 JO JOP/2016/0045A patent/JO3544B1/ar active
- 2016-03-18 US US15/558,240 patent/US20180042910A1/en not_active Abandoned
- 2016-03-18 KR KR1020177026576A patent/KR20170129764A/ko not_active Application Discontinuation
- 2016-03-18 TW TW105108544A patent/TWI723012B/zh not_active IP Right Cessation
- 2016-03-18 DK DK16765135.5T patent/DK3270923T3/da active
- 2016-03-18 SI SI201631316T patent/SI3270923T1/sl unknown
- 2016-03-18 PL PL16765135T patent/PL3270923T3/pl unknown
- 2016-03-18 TN TNP/2017/000369A patent/TN2017000369A1/en unknown
- 2016-03-18 SG SG11201707012YA patent/SG11201707012YA/en unknown
- 2016-03-18 JP JP2017547186A patent/JP6869893B2/ja active Active
- 2016-03-18 HU HUE16765135A patent/HUE055387T2/hu unknown
- 2016-03-18 PE PE2017001525A patent/PE20171621A1/es unknown
- 2016-03-18 PT PT167651355T patent/PT3270923T/pt unknown
- 2016-03-18 MY MYPI2017703320A patent/MY196076A/en unknown
- 2016-03-18 AR ARP160100730A patent/AR103972A1/es unknown
- 2016-03-18 RS RS20211061A patent/RS62311B1/sr unknown
- 2016-03-18 CR CR20170405A patent/CR20170405A/es unknown
- 2016-03-18 LT LTEP16765135.5T patent/LT3270923T/lt unknown
- 2016-03-18 CN CN201680012849.8A patent/CN107405341A/zh active Pending
- 2016-03-18 CA CA2978426A patent/CA2978426A1/en not_active Abandoned
- 2016-03-18 EP EP16765135.5A patent/EP3270923B1/en active Active
- 2016-03-18 AU AU2016234211A patent/AU2016234211B2/en not_active Ceased
- 2016-03-18 GE GEAP201614604A patent/GEP20197007B/en unknown
- 2016-03-18 MX MX2017012020A patent/MX2017012020A/es unknown
- 2016-03-18 WO PCT/JP2016/059788 patent/WO2016148308A1/en active Application Filing
- 2016-03-18 BR BR112017018165A patent/BR112017018165A2/pt not_active Application Discontinuation
- 2016-03-18 ES ES16765135T patent/ES2884846T3/es active Active
- 2016-03-18 UA UAA201709985A patent/UA123578C2/uk unknown
- 2016-03-18 EA EA201792070A patent/EA032511B1/ru unknown
-
2017
- 2017-08-29 IL IL254196A patent/IL254196A0/en unknown
- 2017-08-29 SV SV2017005527A patent/SV2017005527A/es unknown
- 2017-08-29 CO CONC2017/0008814A patent/CO2017008814A2/es unknown
- 2017-09-08 ZA ZA2017/06136A patent/ZA201706136B/en unknown
- 2017-09-11 DO DO2017000206A patent/DOP2017000206A/es unknown
- 2017-09-15 CL CL2017002351A patent/CL2017002351A1/es unknown
- 2017-10-18 EC ECIEPI201769712A patent/ECSP17069712A/es unknown
-
2018
- 2018-07-11 HK HK18108966.3A patent/HK1249059A1/zh unknown
-
2021
- 2021-08-20 HR HRP20211340TT patent/HRP20211340T1/hr unknown
- 2021-08-25 CY CY20211100762T patent/CY1124459T1/el unknown
- 2021-09-03 US US17/466,772 patent/US20210393606A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019003636A1 (es) | Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson. | |
BR112018003985A2 (pt) | macrociclos peptidomiméticos e usos dos mesmos | |
BR112017009497A2 (pt) | polinucleotídeos de aadc para o tratamento da doença de parkinson | |
CR20160485A (es) | Compuesto de ciclopropanamina y sus usos | |
SA518400356B1 (ar) | مثبطات الأرجيناز واستخداماتها العلاجية | |
CL2016001895A1 (es) | Compuestos | |
CL2016001595A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6. | |
GT201700223A (es) | Imidazopirazinonas como inhibidores de pde 1 | |
BR112017028468A2 (pt) | formulação sólida oral, e método para preparar uma formulação sólida oral | |
MX2019003373A (es) | Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos. | |
WO2015066302A3 (en) | Compositions, methods of use, and methods of treatment | |
MX2017016774A (es) | Agente terapeutico para la fibrosis. | |
MX2019008338A (es) | Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco. | |
MX2019002901A (es) | Tratamiento de esclerosis multiple con chs-131. | |
AR106559A1 (es) | Suspensión acuosa para administración oral y método para su preparación | |
DOP2017000206A (es) | Agente terapéutico para disfunción del lóbulo frontal | |
WO2017106367A8 (en) | Method of treating neurodegenerative disorders by rescuing alpha-synuclein toxicity | |
PH12018501991A1 (en) | Pharmaceutical composition for use in treating fibrosis | |
CL2018002930A1 (es) | (+)-azasetron para uso en el tratamiento de desórdenes de oído. | |
AR112460A1 (es) | Combinaciones farmacéuticas | |
WO2018094035A3 (en) | Ligand ionophore conjugates | |
BR112018002138A2 (pt) | composto 2-(5 s-metil-2-oxo-4r-fenil-pirrolidin-1-il)-acetamida, uso, composição farmacêutica e método para a profilaxia ou o tratamento de convulsões | |
BR112018071123A2 (pt) | (+)-azasetron para uso no tratamento de distúrbios de ouvido | |
PH12017501982A1 (en) | Pharmaceutical compound | |
IT201600072450A1 (it) | Composizione farmaceutica a base di cellulasi per l’uso nel trattamento di malattie oculari. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |